Natera,Inc. (NASDAQ:NTRA) Files An 8-K Results of Operations and Financial Condition

0

Natera,Inc. (NASDAQ:NTRA) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial
Condition.

On March7, 2017, Natera,Inc. (Natera) issued a press release
announcing its results for its fourth quarter and fiscal year
ended December31, 2016. A copy of the press release is furnished
herewith as Exhibit99.1 to this Current Report on Form8-K/A and
is incorporated herein by reference.

The information in this Current Report on Form8-K/A shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act) or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, regardless of any
general incorporation language in such filing, unless expressly
incorporated by reference in such filing.

Item 9.01. Financial Statements and
Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Press Release dated March7, 2017.


About Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).

Natera, Inc. (NASDAQ:NTRA) Recent Trading Information

Natera, Inc. (NASDAQ:NTRA) closed its last trading session up +0.41 at 8.41 with 251,946 shares trading hands.